| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/17/2005 | US20050059679 Novel hexacyclic compounds |
| 03/17/2005 | US20050059677 Pyralopyridines, process for their preparation and use as therapeutic compounds |
| 03/17/2005 | US20050059676 Cyclic pyrazinoylguanidine sodium channel blockers |
| 03/17/2005 | US20050059675 Antidepressants; N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide; antagonist of adrenergic receptor, serotonin receptor; anxiety, schizophrenia, Parkinson's disease, cognitive disorders, schizophrenia |
| 03/17/2005 | US20050059674 reducing granulation tissue in humans having otitis and an open tympanic membrane comprising topically applying an aqueous suspension composition containing a combination of ciprofloxacin and dexamethasone |
| 03/17/2005 | US20050059668 Substituted acylpiperazine derivatives |
| 03/17/2005 | US20050059667 pH-dependent binder controls rate of dissolution of tablet; cardiovascular disease |
| 03/17/2005 | US20050059666 CCR5 antagonists useful for treating AIDS |
| 03/17/2005 | US20050059665 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 03/17/2005 | US20050059664 Novel methods for identifying improved, non-sedating alpha-2 agonists |
| 03/17/2005 | US20050059663 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient |
| 03/17/2005 | US20050059662 Substituted quinazolinone compounds |
| 03/17/2005 | US20050059661 Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| 03/17/2005 | US20050059660 Novel combination |
| 03/17/2005 | US20050059659 Carotenoid analogs or derivatives for controlling C-reactive protein levels |
| 03/17/2005 | US20050059658 N-(2,4-Difluorophenyl)-N'-[3-(4,4-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridazinyl)-phenyl]urea and intermediates; antiviral |
| 03/17/2005 | US20050059657 Aminoisoxazole derivatives active as kinase inhibitors |
| 03/17/2005 | US20050059656 Heterocyclic, tricyclic or phenothiazine compounds where compound has at least a two member central ring; used for preventing cell death in pathological states in which mitochondria contribute to cell death cascade; treatment of stroke, heart attack, neurological insult, brain trauma, spinal cord injury |
| 03/17/2005 | US20050059655 Nitrosated and nitrosylated diuretic compounds, compositions and methods of use |
| 03/17/2005 | US20050059654 Method for treatment of depression and anxiety disorders by combination therapy |
| 03/17/2005 | US20050059652 Open chain prolyl urea-related modulators of androgen receptor function |
| 03/17/2005 | US20050059649 Fungicide |
| 03/17/2005 | US20050059647 Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
| 03/17/2005 | US20050059646 Use of 4-androstene-3,6,17-trione to elevate testosterone levels and the testosterone/estrogen ratio in males |
| 03/17/2005 | US20050059645 Methods for the treatment of male and female sexual dysfunction |
| 03/17/2005 | US20050059644 Including one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid |
| 03/17/2005 | US20050059643 Medicaments for inhalation comprising a steroid and a betamimetic |
| 03/17/2005 | US20050059642 Plant fungicides and bactericides; antibiotic resistant staphylococcus and enterococcus; turf grasses; improved chemical resistance and stability |
| 03/17/2005 | US20050059641 Comprising an analog of 1,25(OH)2D3, such as 1,25(OH)2D3-3-BE or 25(OH)2D3-3-BE, wherein said analog is alkylated or acylated; for the treatment of prostate cancer and metabolic diseases, such as psoriasis |
| 03/17/2005 | US20050059640 comprises valacyclovir hydrochloride, minocycline hydrochloride, and metronidazole |
| 03/17/2005 | US20050059639 Ophthalmic compositions and method for treating eye discomfort and pain |
| 03/17/2005 | US20050059638 Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders |
| 03/17/2005 | US20050059636 For modulation of apoptosis; anticancer agents |
| 03/17/2005 | US20050059635 Astaxanthin, beta-carotene, zeanthin, canthaxanthin |
| 03/17/2005 | US20050059634 Compositions, and methods that inhibit the formation and/or activity of Alzheimer's disease diffusible ligands(ADDLs), and, consequently, are useful in the treatment of Alzheimer's disease and other diseases and conditions associated with ADDLs |
| 03/17/2005 | US20050059632 Synthesis of beta-L-2'-deoxy nucleosides |
| 03/17/2005 | US20050059628 Modulation of beta-catenin/TCF-activated transcription |
| 03/17/2005 | US20050059627 Administering antisense oligonucleotides against the mRNA of corticotropin releasing factor subtype-2 (CRF2) receptor; treating anxiety, obsessive-compulsive disorder, panic disorders, post-traumatic stress, phobias and depression |
| 03/17/2005 | US20050059626 Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
| 03/17/2005 | US20050059625 Immunostimulatory nucleic acid molecules |
| 03/17/2005 | US20050059621 preventing apoptosis in neurons that occurs in the presence of beta -amyloid protein, during or after hypoxia or when the neuron exhibits an elevated intracellular calcium concentrations, comprising administering tyrosine kinase inhibitors; treating neurodegenerative diseases |
| 03/17/2005 | US20050059620 Promoter driven tissue specific cytotoxic agents and title methods of use |
| 03/17/2005 | US20050059619 Immunostimulatory nucleic acids |
| 03/17/2005 | US20050059617 Novel anitsense oligonucleotide derivatives against to hepatitis c virus |
| 03/17/2005 | US20050059616 administering flavonoids and optionally vitamin E or excipients for the prophylaxis of bone or cardiovascular disorders, headaches, hypertension, cancers, leukemia, arteriosclerosis, Alzheimer's disease, inflammatory diseases, rheumatic diseases, acne, alopecia or psoriasis |
| 03/17/2005 | US20050059615 saturated complexes of steroids with cyclodextrins, used for enhancing mucous membrane bioavailability of sex hormones or antiinflammatory agents |
| 03/17/2005 | US20050059613 Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
| 03/17/2005 | US20050059610 Glutamine for use in treating injury |
| 03/17/2005 | US20050059609 New alpha crystalline form of perindopril tert-butylamine salt |
| 03/17/2005 | US20050059608 Pharmaceutical compounds |
| 03/17/2005 | US20050059607 Process for preparing peptidyl heterocyclic ketone derivatives |
| 03/17/2005 | US20050059606 hexapeptides including enantiomers, stereoisomers and tautomers, used as enzyme inhibitors for prophylaxis or prevention of viral diseases |
| 03/17/2005 | US20050059594 Administering macrophage derived factor; oncomodulin |
| 03/17/2005 | US20050059589 Such as cutaneous, ocular, nasal and bronchial allergic disease; interleukins and tumor necrosis factor receptors; competitive binding |
| 03/17/2005 | US20050059586 For increasing expression of human presenilin; for treatment of neurodegenerative diseases, Alzheimer's disease; drug screening |
| 03/17/2005 | US20050059581 Endometrial/epithelial cancer; peroxisome proliferator-activated receptor gamma agonists such as pioglitazone and rosiglitazone |
| 03/17/2005 | US20050059579 Dietary and pharmaceutical compositions for management and treatment of oxidative stress |
| 03/17/2005 | US20050059577 Glycosylphosphatidylinositol containing polypeptides |
| 03/17/2005 | US20050059573 comprising at least one dose of an orally administrable fluoropyrimidine prodrug or precursor and at least one dose of a topical composition comprising uracil and a pharmaceutically acceptable carrier or excipient |
| 03/17/2005 | US20050059144 MHC class II antigen-presenting systems and methods for activating CD4+ T cells |
| 03/17/2005 | US20050059116 Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents |
| 03/17/2005 | US20050059108 Expression vector comprising nucleotide sequences coding neurotransmitter for use in prevention and treatment of obesity, anorexia, energy imbalance, diabetes, dyslipidemia, hypertension and/or insulin resistance |
| 03/17/2005 | US20050059099 PSCA: prostate stem cell antigen and uses thereof |
| 03/17/2005 | US20050059093 Method for detecting modulators of Notch signalling |
| 03/17/2005 | US20050059090 For treatment/prevention of cancer, autoimmune disease, psoriasis, restenosis, and cardiovascular disease |
| 03/17/2005 | US20050059067 Using restriction fragment length polymorphism in tyrosine kinase varian t as diagnostic tool in detection of cell proliferative and inflammatory disorders |
| 03/17/2005 | US20050059008 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 03/17/2005 | US20050059006 Using presence of polymorphism in ciliary neurotrophic factor (CNTF) gene sequences as diagnostic indicator for lloperidone treatment of psychotic disorders |
| 03/17/2005 | US20050059002 Novel serine protease |
| 03/17/2005 | US20050058982 Modified small interfering RNA molecules and methods of use |
| 03/17/2005 | US20050058767 Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities |
| 03/17/2005 | US20050058734 Relieving pain by injecting or infiltrating implantable dose of a capsaicinoid to denervate and vasoconstrictor; cancer, trauma, headache, diabetes, arthritic and/or neuropathic pain; local anesthetics |
| 03/17/2005 | US20050058733 Health food products |
| 03/17/2005 | US20050058732 Herbal pharmaceutical composition for treating siriasis and its process |
| 03/17/2005 | US20050058731 Treatment for cuticles or skin tissue; may also comprise avocado oil, primrose oil, juniper oil, grapefruit oil, chamomile oil, lavender oil with an effective amount of triclosan antifungal/antimicrobial agent |
| 03/17/2005 | US20050058730 Dry powdered extract from medicinal herbs mixed with vitamins, minerals, sheep liver and/or carrot root; health foods, cakes, candy, bread, chocolate |
| 03/17/2005 | US20050058729 Administering extracts of pepper, ginger and related plants containing vanillyl and piperidine compounds such as piperine and/or chavicine ; topical fungicides and bactericides for eyes, ears, and skin |
| 03/17/2005 | US20050058728 Administering rosehips, resveratrol, astaxanthin, blackberry, blueberry, and/or elderberry to inhibit interleukin synthesis; antiinflammatory agents; cardiovascular disorders, pain, stiffness |
| 03/17/2005 | US20050058725 Gelatinase inhibitors; anticancer agents |
| 03/17/2005 | US20050058724 Fluid therapy with l-lactate and/or pyruvate anions |
| 03/17/2005 | US20050058720 Administering thiomolybdate to bind copper and form tripartite complex with protein; ocular, corneal or retinal/choroidal neovascularization, glaucoma, diabetes, delayed wound healing, burns, Osler-Weber Syndrome, psoriasis, parasitic diseases or atherosclerosis; antitumor and anticarcinogenic agents |
| 03/17/2005 | US20050058718 Liquid additive and health pill reduce toxicity in tobacco smoke; health, treating nicotine addiction to quit smoking; decreasing dopamine and glutamic acid with copper and manganese compounds; vitamin B6 turns glutamic acid into g-aminobutyric acid; antioxidant use of vitamin C, E, & A |
| 03/17/2005 | US20050058715 Composition containing a marine-derived inorganic substance and chitin/chitosan, and method of producing the composition |
| 03/17/2005 | US20050058711 Impermeable pouch having opposing walls defining a reservoir space therebetween; second wall includes plurality of openings defining diffusion area; coiled wire configured for fluid flow; thin envelope applied to patient's skin; transdermal drug delivery |
| 03/17/2005 | US20050058707 Time-release dosage form delivered as dry or erodible solid at uniform rate contains polyoxyethylene glycol and/or polyvinylpyrrolidone carrier and disintegrant; free of surfactant |
| 03/17/2005 | US20050058706 Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol |
| 03/17/2005 | US20050058702 Compositions capable of facilitating penetration across a biological barrier |
| 03/17/2005 | US20050058698 The use of liposomes for treatment of inflammation and autoimmune disorders in mammals by reduction of Tumor necrosis factor |
| 03/17/2005 | US20050058696 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 03/17/2005 | US20050058695 Norethindrone sustained release formulations and methods associated therewith |
| 03/17/2005 | US20050058673 Decontamination of vegetables, meats or fruits by disinfection of such with antimicrobial solution containing lipid and enhancer such as bacteriocins, sugars and enzymes |
| 03/17/2005 | US20050058671 synergistic efficacy; polar lipid supplement which contains significant amounts of polar lipids and antioxidants; soluble beta-glucan fiber; and amino acid such as L-threonine |
| 03/17/2005 | US20050058670 Oral itraconazole composition which is not affected by ingested food and process for preparing same |
| 03/17/2005 | US20050058657 Vaccines for treatment of Aids |
| 03/17/2005 | US20050058647 Newly identified polypeptide and polynucleotides for diagnosis of new compounds |
| 03/17/2005 | US20050058641 Tolerance induction and maintenance in hematopoietic stem cell allografts |
| 03/17/2005 | US20050058637 Therapy, prevention of viral infections; obtaining viron sample; incubation, monitoring, calibration: using antithrombin agent |
| 03/17/2005 | US20050058635 Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders |
| 03/17/2005 | US20050058628 Nuclear reprogramming of cells for therapeutic use |
| 03/17/2005 | US20050058626 Vaccine against pathogens |